Company profile: Armgo Pharma
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics that repair leaky Ryanodine Receptor (RyR) calcium channels for cardiac, skeletal muscular, and neurological disorders. Offers Rycals, including ARM210 (S48168), in clinical development for RYR1-Related Myopathy (RYR1-RM) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
Products and services
- Rycals: Engineers small-molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels to address disorders caused by these leaks across cardiac, skeletal muscular, and neurological indications
- ARM210 (S48168): Clinical-stage Rycal-class small-molecule that repairs leaky Ryanodine Receptor channels, in development to treat RYR1-Related Myopathy (RYR1-RM) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Small-Molecule Therapeutics Development: Develops small-molecule medicines for debilitating cardiac, skeletal muscular, and neurological disorders, leveraging Rycal mechanisms that repair leaky Ryanodine Receptor calcium channels in relevant disease contexts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Armgo Pharma
InterVene
HQ: United States
Website
- Description: Provider of minimally invasive medical devices and therapies for chronic venous disease, particularly deep vein valve failure. The company's BlueLeaf™ Endovenous Valve Formation System offers a non-implantable solution to address severe venous conditions in the legs, aiming to improve patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InterVene company profile →
Marea Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies leveraging human genetics to develop next-generation treatments for cardiometabolic diseases. Pipeline includes MAR001, a monoclonal antibody targeting ANGPTL4 to reduce remnant cholesterol and triglycerides and improve adipose tissue function (Phase 2), MAR002, an anti-growth hormone receptor antibody for acromegaly, and undisclosed discovery programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marea Therapeutics company profile →
AtheroGenics
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on developing antioxidants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AtheroGenics company profile →
Prevencio
HQ: United States
Website
- Description: Provider of multi-proteomic cardiovascular blood tests: HART CVE uses a machine learning algorithm to predict 1-year risk of heart attack, stroke, or cardiac death; HART CADhs detects obstructive coronary artery disease; HART PAD diagnoses obstructive peripheral artery disease; HART AS diagnoses and monitors aortic valve stenosis (98% exclusion accuracy); HART Amputation Risk assesses amputation risk (87% accuracy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevencio company profile →
Avive
HQ: United States
Website
- Description: Provider of an automated external defibrillator for emergency use that delivers electrical therapy to stop arrhythmias and restore normal heart rhythm, and software solutions to support the use and management of the device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avive company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Armgo Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Armgo Pharma
2.2 - Growth funds investing in similar companies to Armgo Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Armgo Pharma
4.2 - Public trading comparable groups for Armgo Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →